{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T07:28:25Z","timestamp":1794641305289,"version":"4.9.1"},"reference-count":33,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"10","license":[{"start":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T00:00:00Z","timestamp":1681344000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Venetoclax+azacitidine is the standard of care for newly-diagnosed patients with acute myeloid leukemia (AML) for whom intensive chemotherapy is inappropriate. Efforts to optimize this regimen are necessary. We designed a clinical trial to investigate two hypotheses: i) higher doses of venetoclax are tolerable and more effective, and ii) azacitidine can be discontinued after deep remissions. Forty-two newly diagnosed AML patients were enrolled in the investigator-initiated High Dose Discontinuation Azacitidine+Venetoclax (HiDDAV) Study (clinicaltrials gov. Identifier: NCT03466294). Patients received one to three \u201cinduction\u201d cycles of venetoclax 600 mg daily with azacitidine. Responders received MRD-positive or MRDnegative \u201cmaintenance\u201d arms: azacitidine with 400 mg venetoclax or 400 mg venetoclax alone, respectively. The toxicity profile of HiDDAV was similar to 400 mg venetoclax. The overall response rate was 66.7%; the duration of response (DOR), event-free survival (EFS) and overall survival were 12.9, 7.8 and 9.8 months, respectively. The MRD negativity rate was 64.3% by flow cytometry and 25.0% when also measured by droplet digital polymerase chain recation. MRD-negative patients by flow cytometry had improved DOR and EFS; more stringent measures of MRD negativity were not associated with improved OS, DOR or EFS. Using MRD to guide azacitidine discontinuation did not lead to improved DOR, EFS or OS compared to patients who discontinued azacitidine without MRD guidance. Within the context of this study design, venetoclax doses &gt;400 mg with azacitidine were well tolerated but not associated with discernible clinical improvement, and MRD may not assist in recommendations to discontinue azacitidine. Other strategies to optimize, and for some patients, de-intensify, venetoclax+azacitidine regimens are needed.<\/jats:p>","DOI":"10.3324\/haematol.2023.282681","type":"journal-article","created":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T03:40:16Z","timestamp":1681357216000},"page":"2616-2625","source":"Crossref","is-referenced-by-count":17,"title":["Higher-dose venetoclax with measurable residual disease-guided azacitidine discontinuation in newly diagnosed acute myeloid leukemia"],"prefix":"10.3324","volume":"108","author":[{"given":"Jonathan A.","family":"Gutman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Winters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Kent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Amaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"McMahon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clayton","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig T.","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Minhajuddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Schowinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Tobin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Falco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constance","family":"Brecl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phuong","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connor","family":"Sohalski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Dell-Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Ondracek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Abbott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A.","family":"Pollyea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2023,4,13]]},"reference":[{"key":"52320","doi-asserted-by":"crossref","unstructured":"DiNardo CD, Jonas BA, Pullarkat V. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020; 383(7):617-629.","DOI":"10.1056\/NEJMoa2012971"},{"key":"52321","doi-asserted-by":"crossref","unstructured":"Pratz KW, Jonas BA, Pullarkat V. Measurable residual disease response and prognosis in treatment-naive acute myeloid leukemia with venetoclax and azacitidine. J Clin Oncol. 2022; 40(8):855-865.","DOI":"10.1200\/JCO.21.01546"},{"key":"52322","doi-asserted-by":"crossref","unstructured":"DiNardo CD, Pratz KW, Letai A. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol. 2018; 2:216-228.","DOI":"10.1016\/S1470-2045(18)30010-X"},{"key":"52323","doi-asserted-by":"crossref","unstructured":"DiNardo CD, Pratz K, Pullarkat V. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019; 133(1):7-17.","DOI":"10.1182\/blood-2018-08-868752"},{"key":"52324","doi-asserted-by":"crossref","unstructured":"Chua CC, Hammond D, Kent A. Treatment-free remission after ceasing venetoclax-based therapy in patients with acute myeloid leukemia. Blood Adv. 2022; 6(13):3879-3883.","DOI":"10.1182\/bloodadvances.2022007083"},{"key":"52325","doi-asserted-by":"crossref","unstructured":"Zeidan AM, Hu X, Zhu W. Association of provider experience and clinical outcomes in patients with myelodysplastic syndromes receiving hypomethylating agents. Leuk Lymphoma. 2020; 61(2):397-408.","DOI":"10.1080\/10428194.2019.1663423"},{"key":"52326","doi-asserted-by":"crossref","unstructured":"Zeidan AM, Salimi T, Epstein RS. Real-world use and outcomes of hypomethylating agent therapy in higher-risk myelodysplastic syndromes: why are we not achieving the promise of clinical trials?. Future Oncol. 2021; 36:5163-5175.","DOI":"10.2217\/fon-2021-0936"},{"key":"52327","doi-asserted-by":"crossref","unstructured":"Short NJ, Zhou S, Fu C. Association of measurable residual disease with survival outcomes in patients with acute myeloid leukemia: a systematic review and meta-analysis. JAMA Oncol. 2020; 6(12):1890-1899.","DOI":"10.1001\/jamaoncol.2020.4600"},{"key":"52328","doi-asserted-by":"crossref","unstructured":"Pollyea DA, Stevens BM, Jones CL. Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia. Nat Med. 2018; 24(12):1859-1866.","DOI":"10.1038\/s41591-018-0233-1"},{"key":"52329","doi-asserted-by":"crossref","unstructured":"Jones CL, Stevens BM, D'Alessandro A. Cysteine depletion targets leukemia stem cells through inhibition of electron transport complex II. Blood. 2019; 134(4):389-394.","DOI":"10.1182\/blood.2019898114"},{"key":"52330","doi-asserted-by":"crossref","unstructured":"Jones CL, Stevens BM, D'Alessandro A. Inhibition of amino acid metabolism selectively targets human leukemia stem cells. Cancer Cell. 2018; 34(5):724-740.","DOI":"10.1016\/j.ccell.2018.10.005"},{"key":"52331","unstructured":"Lawless JF. Statistical models and methods for lifetime data. New York: Wiley. 1982."},{"key":"52332","doi-asserted-by":"crossref","unstructured":"Oken MM, Creech RH, Tormey DC. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982; 6:649-55.","DOI":"10.1097\/00000421-198212000-00014"},{"key":"52333","doi-asserted-by":"crossref","unstructured":"Dohner H, Estey E, Grimwade D. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017; 129(4):424-447.","DOI":"10.1182\/blood-2016-08-733196"},{"key":"52334","doi-asserted-by":"crossref","unstructured":"Abbott D, Cherry E, Amaya M. The propriety of upgrading responses to venetoclax + azacitidine in newly diagnosed patients with acute myeloid leukemia. Leuk Lymphoma. 2021; 62(6):1466-1473.","DOI":"10.1080\/10428194.2020.1864358"},{"key":"52335","doi-asserted-by":"crossref","unstructured":"Bennett JM, Catovsky D, Daniel MT. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol. 1976; 4:451-845.","DOI":"10.1111\/j.1365-2141.1976.tb03563.x"},{"key":"52336","doi-asserted-by":"crossref","unstructured":"Heuser M, Freeman SD, Ossenkoppele GJ. 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2021; 138(26):2753-2767.","DOI":"10.1182\/blood.2021013626"},{"key":"52337","doi-asserted-by":"crossref","unstructured":"Gale RE, Green C, Allen C. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood. 2008; 111(5):2776-2784.","DOI":"10.1182\/blood-2007-08-109090"},{"key":"52338","doi-asserted-by":"crossref","unstructured":"Jongen-Lavrencic M, Grob T, Hanekamp D. Molecular minimal residual disease in acute myeloid leukemia. N Engl J Med. 2018; 378(13):1189-1199.","DOI":"10.1056\/NEJMoa1716863"},{"key":"52339","doi-asserted-by":"crossref","unstructured":"Norsworthy KJ, Gao X, Ko CW. Response rate, event-free survival, and overall survival in newly diagnosed acute myeloid leukemia: US Food and Drug Administration trial-level and patient-level analyses. J Clin Oncol. 2022; 40(8):847-854.","DOI":"10.1200\/JCO.21.01548"},{"key":"52340","doi-asserted-by":"crossref","unstructured":"Rausch CR, DiNardo CD, Maiti A. Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia. Cancer. 2021; 127(14):2489-2499.","DOI":"10.1002\/cncr.33508"},{"key":"52341","doi-asserted-by":"crossref","unstructured":"Winters AC, Bosma G, Abbott D. Outcomes are similar after allogeneic hematopoietic stem cell transplant for newly diagnosed acute myeloid leukemia patients who received venetoclax + azacitidine versus intensive chemotherapy. Transplant Cell Ther. 2022; 28(10):694.","DOI":"10.1016\/j.jtct.2022.07.022"},{"key":"52342","doi-asserted-by":"crossref","unstructured":"Jonas BA, Pollyea DA. How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia. Leukemia. 2019; 33(12):2795-2804.","DOI":"10.1038\/s41375-019-0612-8"},{"key":"52343","doi-asserted-by":"crossref","unstructured":"Pollyea DA, Bixby D, Perl A. NCCN guidelines insights: acute myeloid leukemia, version 2.2021. J Natl Compr Canc Netw. 2021; 19(1):16-27.","DOI":"10.6004\/jnccn.2021.0002"},{"key":"52344","doi-asserted-by":"crossref","unstructured":"Wei AH, Dohner H, Pocock C. Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission. N Engl J Med. 2020; 383(26):2526-2537.","DOI":"10.1056\/NEJMoa2004444"},{"key":"52345","doi-asserted-by":"crossref","unstructured":"Zainaldin C, Arora S, Bathini S. Dismal survival outcomes of patients with acute myeloid leukemia after failure of venetoclax with hypomethylating agents. Leuk Lymphoma. 2022; 63(13):3245-3248.","DOI":"10.1080\/10428194.2022.2113530"},{"key":"52346","doi-asserted-by":"crossref","unstructured":"Maiti A, Rausch CR, Cortes JE. Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens. Haematologica. 2021; 106(3):894-898.","DOI":"10.3324\/haematol.2020.252569"},{"key":"52347","doi-asserted-by":"crossref","unstructured":"Bewersdorf JP, Shallis RM, Derkach A. Efficacy of FLT3 and IDH1\/2 inhibitors in patients with acute myeloid leukemia previously treated with venetoclax. Leuk Res. 2022; 122:106942.","DOI":"10.1016\/j.leukres.2022.106942"},{"key":"52348","doi-asserted-by":"crossref","unstructured":"Zhang A, Johnson T, Abbott D. Incidence of invasive fungal infections in patients with previously untreated acute myeloid leukemia receiving venetoclax and azacitidine. Open Forum Infect Dis. 2022; 9(10):ofac486.","DOI":"10.1093\/ofid\/ofac486"},{"key":"52349","doi-asserted-by":"crossref","unstructured":"Pollyea DA, Winters A, McMahon C. Venetoclax and azacitidine followed by allogeneic transplant results in excellent outcomes and may improve outcomes versus maintenance therapy among newly diagnosed AML patients older than 60. Bone Marrow Transplant. 2022; 57(2):160-166.","DOI":"10.1038\/s41409-021-01476-7"},{"key":"52350","doi-asserted-by":"crossref","unstructured":"Pollyea DA. Acute myeloid leukemia drug development in the post-venetoclax era. Am J Hematol. 2019; 94(9):959-962.","DOI":"10.1002\/ajh.25556"},{"key":"52351","doi-asserted-by":"crossref","unstructured":"Pollyea DA. Venetoclax in AML: where we are and where we are headed. Clin Lymphoma Myeloma Leuk. 2020; 20(Suppl 1):S25-S26.","DOI":"10.1016\/S2152-2650(20)30450-X"},{"key":"52352","doi-asserted-by":"crossref","unstructured":"Cherry EM, Abbott D, Amaya M. Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia. Blood Adv. 2021; 5(24):5565-5573.","DOI":"10.1182\/bloodadvances.2021005538"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.282681\/75534","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.282681\/76071","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11054\/75534","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:03:55Z","timestamp":1794045835000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2023.282681"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,13]]},"references-count":33,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,10,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2023.282681","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4,13]]}}}